• Regulatory NewsRegulatory News

    FDA Issues Guidance on Drugs to Prevent Delayed Graft Function in Kidney Transplant Patients

    The US Food and Drug Administration (FDA) on Wednesday issued new draft guidance detailing its expectations for drugs intended to treat delayed graft function (DGF) in kidney transplant patients. DGF is a condition that involves suboptimal kidney function immediately following a kidney transplantation, and is usually defined as the need for dialysis within seven days of receiving a transplant, though FDA notes there are other accepted definitions for the condition. Ther...